Objective The main objective of the proposal is to develop a new target-specific delivery system for the treatment of malignant glioma. For that purpose we have cloned a new fusion gene "Cave-in" which contains intracellular and membrane-spanning domains of scavenger receptor legated to avid in which will form the extra cellular domain of the fusion protein. Cave-in will be transfixed to target tissue with local gene therapy via catheter delivery or during surgical operation with adenovirus or pseudotyped retrovirus technology. Targeted treatment is achieved by binding of biotinylated compounds to Cave-in, which will be only expressed in the transfixed tissue. Fields of science medical and health sciencesmedical biotechnologygenetic engineeringgene therapynatural sciencesbiological sciencesbiochemistrybiomoleculesproteinsmedical and health sciencesclinical medicineoncology Programme(s) FP5-LIFE QUALITY - Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002 Topic(s) 1.1.1.-3. - Key action The "Cell factory" Call for proposal Data not available Funding Scheme CSC - Cost-sharing contracts Coordinator UNIVERSITY OF KUOPIO EU contribution No data Address Savilahdentie 9 1627 KUOPIO Finland See on map Total cost No data Participants (3) Sort alphabetically Sort by EU Contribution Expand all Collapse all ARK THERAPEUTICS LTD. United Kingdom EU contribution No data Address Warren Mews 6 W1T 6AR LONDON See on map Total cost No data ISTITUTO EUROPEO DI ONCOLOGIA SRL Italy EU contribution No data Address Via Filodrammatici 8 20121 MILANO See on map Total cost No data UNIVERSITY COLLEGE LONDON United Kingdom EU contribution No data Address Mortimer Street The Middlesex Hospital W1N 8AA London See on map Total cost No data
